Technical Analysis for ONCT - Oncternal Therapeutics, Inc.

Grade Last Price % Change Price Change
D 7.80 -2.74% -0.22
ONCT closed down 2.74 percent on Monday, March 18, 2024, on 1.28 times normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or bounces.
2 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down

Date Alert Name Type % Chg
180 Bearish Setup Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Lower Bollinger Band Walk Weakness 0.00%
Below Lower BB Weakness 0.00%
Gapped Down Weakness 0.00%
Lower Bollinger Band Touch Weakness 0.00%
Oversold Stochastic Weakness 0.00%
200 DMA Support Bullish -2.74%
Lower Bollinger Band Walk Weakness -2.74%
Gapped Down Weakness -2.74%

   Recent Intraday Alerts

Alert Time
60 Minute Opening Range Breakdown about 16 hours ago
Gap Down Closed about 19 hours ago
Rose Above Previous Day's High about 19 hours ago
Up 3% about 19 hours ago
Up 2% about 19 hours ago

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Oncternal Therapeutics, Inc. Description

Oncternal Therapeutics is a clinical-stage biopharmaceutical company focused on developing a diverse pipeline of product candidates for the treatment of cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody designed to inhibit the ROR1 receptor that is being evaluated in a Phase 1/2 clinical trial in combination with ibrutinib for the treatment of CLL and MCL, and TK-216, a small-molecule compound that is designed to inhibit ETS-family oncoproteins, which is being evaluated in a Phase 1 clinical trial alone and in combination with vincristine as a treatment for Ewing sarcoma, a rare pediatric cancer. In addition, Oncternal has a CAR-T product candidate that targets ROR1, which is currently in preclinical development as a potential treatment for hematologic cancers and solid tumors.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Solid Tumors Clinical Development Treatment Of Cancer Monoclonal Antibody Organic Compounds Chemical Compounds Drug Development Sarcoma Hematologic Cancers

Is ONCT a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 17.6
52 Week Low 5.25
Average Volume 14,206
200-Day Moving Average 7.56
50-Day Moving Average 8.83
20-Day Moving Average 9.16
10-Day Moving Average 8.94
Average True Range 0.65
RSI (14) 37.50
ADX 24.09
+DI 19.75
-DI 33.43
Chandelier Exit (Long, 3 ATRs) 8.67
Chandelier Exit (Short, 3 ATRs) 9.43
Upper Bollinger Bands 10.45
Lower Bollinger Band 7.87
Percent B (%b) -0.03
BandWidth 28.13
MACD Line -0.22
MACD Signal Line 0.00
MACD Histogram -0.2224
Fundamentals Value
Market Cap 23.09 Million
Num Shares 2.96 Million
EPS -14.40
Price-to-Earnings (P/E) Ratio -0.54
Price-to-Sales 44.37
Price-to-Book 0.79
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 8.57
Resistance 3 (R3) 8.65 8.48 8.44
Resistance 2 (R2) 8.48 8.29 8.44 8.39
Resistance 1 (R1) 8.14 8.16 8.06 8.06 8.35
Pivot Point 7.97 7.97 7.93 7.93 7.97
Support 1 (S1) 7.63 7.78 7.55 7.55 7.25
Support 2 (S2) 7.46 7.65 7.42 7.21
Support 3 (S3) 7.12 7.46 7.16
Support 4 (S4) 7.04